Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

Rhea-AI Summary

Tempest Therapeutics (Nasdaq: TPST) announced that President Tom Dubensky, Ph.D. will participate in a panel on Next Generation Immuno-Oncology Targets at the 2022 William Blair Biotech Focus Conference on July 12, 2022, at 4:10 p.m. ET. The company, based in South San Francisco, focuses on developing first-in-class therapeutics that integrate targeted and immune-mediated mechanisms for treating various tumors. Key clinical programs include TPST-1120 and TPST-1495, advancing through trials as monotherapies and in combination treatments.

President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy Targets

SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class¹ therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Tom Dubensky, Ph.D., will participate in a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the 2022 William Blair Biotech Focus Conference on Tuesday, July 12, 2022 at 4:10 p.m. ET.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing through clinical trials designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1, a DNA repair enzyme that controls activation of the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contact:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media Contact:

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@tempesttx.com

__________________________

^{¹ If approved}

FAQ

What is the focus of Tempest Therapeutics as of July 2022?

Tempest Therapeutics focuses on developing first-in-class therapeutics that combine targeted and immune-mediated mechanisms to treat a variety of tumors.

When will Tom Dubensky speak at the William Blair Biotech Focus Conference?

Tom Dubensky will speak on July 12, 2022, at 4:10 p.m. ET.

What are the key clinical programs mentioned for TPST?

The key clinical programs for Tempest Therapeutics are TPST-1120 and TPST-1495, which are in clinical trials.

What innovative pathway is Tempest Therapeutics developing with TREX-1 inhibition?

Tempest Therapeutics is developing an orally-available inhibitor of TREX-1 to enhance the activation of the cGAS/STING pathway, crucial for anti-tumor immunity.

Where is Tempest Therapeutics headquartered?

Tempest Therapeutics is headquartered in South San Francisco.